

Reflect, Research, and Reconnect

3 steps to help you get ready for your next visit with your care team

Reflect

Taking the initiative to discuss your treatment options with your care team shows that you're committed to your health. Take a moment to reflect on what you want:

What life goals or activities would you like to be able to do as a result of a new treatment? Example: Spend more time with family or participate in outdoor exercise.

Which aspects of your treatment plan would you like to change? Example: I'd prefer a less frequent dosing schedule.

What would make you feel the most confident while managing your condition? Example: Knowing that I'm taking the treatment that best fits my lifestyle.



Research

Check all topics you want to discuss with your care team:

Dosing flexibility Maintaining high trough levels Long-lasting bleed protection Other Preventing spontaneous bleeds Treatment that matches my lifestyle/goals Patient support services



Know your factor

According to the **World Federation** of Hemophilia, increasing factor levels decreases bleed frequency every percentage point counts.



Levels inform bleed risk People with FIX levels >15% have a very low risk for spontaneous bleeds. What are your current levels?



(3)

Reconnect

Be an advocate for yourself. Write down questions and key talking points for your next visit. (Example: "I recently learned about IDELVION—could it be an option for me and my lifestyle?")

Write down your questions, talking points, and notes here:



Remember: Your care team is your ally. The only way to let them know how to help is to speak your mind.





ONLY IDELVION DELIVERS







*Hemophilia FIX Market Assessment. Third-party market research.

⁺Once well-controlled (1 month without spontaneous bleeding or requiring dose adjustments on a weekly dose of <40 IU/kg), people 12 years and older can be transitioned to 14-day dosing.

⁺The average dose for adolescents and adults receiving prophylaxis every 7 days was 37 IU/kg.

^sThe median AsBR for people who started on 7- or 14-day prophylaxis was 0. For people who switched to prophylaxis from on-demand, the median AsBR was 0.7.

AsBR = annualized spontaneous bleed rate.



Want to talk to someone who knows what you're going through? Connect with our Advocate Program[®]



[¶]Advocates are not healthcare providers or medical experts and are compensated by CSL Behring for their time and expenses. For medical questions, contact your physician. Call 1-866-705-9661 or scan above



IMPORTANT SAFETY INFORMATION

IDELVION[®], Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rFIX-FP), is used to control and prevent bleeding episodes in children and adults with hemophilia B. Your doctor might also give you IDELVION before surgical procedures. IDELVION can reduce the number of bleeding episodes when used regularly as prophylaxis.

IDELVION is administered by intravenous injection into the bloodstream and can be self-administered or administered by a caregiver. Do not inject IDELVION without training and approval from your healthcare provider or hemophilia treatment center.

Tell your healthcare provider of any medical condition you might have, including allergies and pregnancy, as well as all medications you are taking. Do not use IDELVION if you know you are allergic to any of its ingredients, including hamster proteins. Tell your doctor if you previously had an allergic reaction to any FIX product.

Stop treatment and immediately contact your healthcare provider if you see signs of an allergic reaction, including a rash or hives, itching, tightness of chest or throat, difficulty breathing, lightheadedness, dizziness, nausea, or a decrease in blood pressure.

Your body can make antibodies, called inhibitors, against Factor IX, which could stop IDELVION from working properly. You might need to be tested for inhibitors from time to time. IDELVION might also increase the risk of abnormal blood clots in your body, especially if you have risk factors. Call your healthcare provider if you have chest pain, difficulty breathing, or leg tenderness or swelling.

The most common side effects of IDELVION are headache and dizziness. These are not the only side effects possible. Tell your healthcare provider about any side effect that you experience, and contact provider immediately if bleeding does not stop after taking IDELVION.

Please see full prescribing information for IDELVION, including patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You can also report side effects to CSL Behring's Pharmacovigilance Department at 1-866-915-6958.

CSL Behring

IDELVION is manufactured by CSL Behring GmbH and distributed by CSL Behring LLC. IDELVION® is a registered trademark of CSL Behring Lengnau AG. ©2024 CSL Behring LLC 1020 First Avenue, PO Box 61501, King of Prussia, PA 19406-0901 USA